FDA Inspection 1237445 — Slate Run Pharmaceuticals

Slate Run Pharmaceuticals — FEI 3012729077

The FDA completed an inspection of Slate Run Pharmaceuticals on Dec 5, 2024 in Columbus, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Dec 5, 2024
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Columbus, OH (United States)

Additional details

Postmarket Adverse Drug Experience (PADE)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.